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Reply to Drs Seale and Donnelly 
The study by Drs Seale and Donnelly confirms previous 
dose-response studies in healthy adults showing a more 
potent systemic activity of fluticasone propionate (FP) than 
that of budesonide (BUD) when delivered from comparable 
devices (l-3). Paediatric data on asthmatic children may be 
interpreted in support of this difference in systemic potency. 
FP exhibited a greater systemic bioactivity than BUD as 
evaluated from free cortisol in 12-h night urine from 
school-children after single doses of FP and BUD delivered 
from comparable devices (4). FP and BUD had similar 
systemic potency in school-children when delivered regu- 
larly from the Diskus and Turbuhaler devices, respectively. 
Free cortisol in diurnal urine and short-term knemometry 
was used as outcome (5). In young children of age l-3 
years, knemometry showed similar systemic activity from 
FP inhaled via the Babyhaler device and BUD inhaled via a 
metalspacer (6). In the latter two paediatric studies, the 
device used to deliver BUD would be expected to provide a 
higher lung dose than the device used to deliver FP (7). 
Since lung dose is the major determinant of systemic 
activity, such data are compatible with adult data showing 
that the FP molecule causes more potent systemic activity 
than the BUD molecule, bearing in mind the important 
effect of the delivery device on systemic bioactivity. 
Together, these data provide very important information 
on the systemic activity of FP in contrast to previous 
claims that FP was without systemic activity within the 
recommended therapeutic dose-range. 
However disappointing as this may be, it should not 
discourage the continued use of inhaled steroids, including 
FP. It is important to emphasize that the documented 
systemic activity is not synonymous of clinical side-effects. 
Clinical side-effects can only be measured by clinically 
relevant outcomes. 
The measurement of systemic activity provides useful 
information about the relative systemic potency of various 
steroid treatments including steroid and delivery devices. 
With proper use of comparative data on efficacy this can 
provide information about the therapeutic index and the 
safer treatment regime. Systemic activity may be measured 
indirectly in numerous ways, including the integration of 
diurnal adrenal function as reflected in plasma or urine, 
measures of bone and connective tissue turn-over, short- 
term growth in children by knemometry and others. How- 
ever, these measures only become clinically relevant if the 
capacity of the adrenal gland to respond adequately to 
stress is impaired, if there is an adverse effect on bone 
formation or statural height velocity, or if other clinically 
relevant outcomes are affected. 
Measures of systemic activity vary in their sensitivity. 
In paediatrics the development has provided increasingly 
sensitive measures of systemic activity, which has revealed 
systemic activity from increasingly lower doses. Doses 
below 16OOpg BUD were considered without apparent 
systemic activity a decade ago, when morning p-cortisol 
was considered state-of-the-art for such a purpose. When 
the use of free cortisol in 24-h urine was adopted, doses of 
c. 8OOpg BUD showed systemic activity (8). The subse- 
quent introduction of knemometry for measurements of 
systemic activity identified activity in doses of 400 pg BUD 
(9). Improved methods will certainly identify systemic 
activity in even lower doses in the future. Obviously, this 
does not mean that the safe dose is becoming equally 
diminished. 
In conclusion, systemic activity should only be used for 
comparisons between various steroid regimes, while safety 
should be studied by clinical outcome. Any consideration as 
to the safety of treatment should, therefore, be restricted to 
clinical outcome. 
HANS BISGAARD, MD, DR MED SCI 
Department of Paediatrics, 
National University Hospital, 
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Reply to Drs Seale and Donnelly 
Drs Seale and Donnelly should provide a dose-range 
context for each of the currently used inhaled steroids 
rather than focusing on their study which contrasts high- 
dose FP with BUD. It is important to underscore the 
starting dose of each compound, since the majority of 
asthmatics with mild/moderate asthma will experience 
minimal (and not clinically significant) HPA axis 
suppression at these recommended doses. 
The authors cite their own study (their ref. 11) that ‘a 
more potent inhaled corticosteroid is insufficient to 
materially improve the topical-to-systemic ratio’, hence, the 
issue of corticosteroids is at the ‘crossroads’. However, their 
investigation was not an efficacy study but merely showed 
the expected cortisol suppression at the high-dose ranges of 
the two compounds studied. They also fail to cite the 
important study of Noonan where high-dose FP allowed 
discontinuation of systemic prednisone, clearly an improve- 
ment for each of those patients in the topical-to-systemic 
ratio. 
Their own study that they cite as evidence for failure of a 
new steroid (FP) to achieve a higher topical-to-systemic 
ratio has clear-cut limitations. This study was performed in 
normal subjects, not asthmatics, as they acknowledge in the 
Discussion. The modest reductions in cortisol profiling at 
the lower doses (800 pug of BUD; 750 pg of FP - not 500 ,ug, 
an error in the manuscript) is not ‘surprising’ but, in fact, 
is expected. These doses are known to reduce cortisol levels 
as that fraction of the inhaled dose that is inhaled into the 
lung (approximately 20% for most compounds) is ulti- 
mately systemically absorbed. Clearly what needs to be 
accomplished is the establishment of bioequivalent dosing 
for each of the inhaled steroids (using the HPA axis as the 
marker of systenzic bioavailability) over broad (low, 
medium, high) dose ranging. With this information, each 
compound could then be compared to the others at 
bioequivalent dosing in eflcacy trials to see if the unique 
properties of a compound favourably alters the efficacy 
profile. 
Finally, it is possible that other tissues and biological end 
points (e.g. growth in children) are even more sensitive 
markers of glucocorticoid ‘toxicity’ than the HPA axis. 
Nevertheless, it is likely that glucocorticoid exposure at 
high dosage, regardless of route of administration, over 
prolonged periods will carry risk. In such patients, it is 
likely that systemic steroids carry an even greater risk due 
to the adverse topical-to-systemic ratio. 
R. G. DLUHY, MD 
Brigham 6 Women’s Hospital, 
Boston, MA 02 115, U.S.A. 
Reply to Drs Seale and Donnelly 
Issues about the safety of inhaled corticosteroids and the 
relative efficacy to safety ratio of different inhaled steroids 
are of considerable clinical importance. I do not think 
Drs Seale and Donnelly’s letter or the paper by Donnelly 
et al. (their ref. 11) which triggered this letter contribute 
much in this regard. Efficacy and safety mean very little in 
isolation; when considering an inhaled corticosteroid one 
needs to consider the ratio of efficacy to safety as the 
authors point out. Information from studies such as 
Donnelly et al. provides information of very limited value 
when performed in normal volunteers with no measures of 
efficacy. It is clear from studies with inhaled fluticasone, 
&-agonists and diosodium cromoglycate that normal sub- 
jects absorb far more inhaled drugs from their lungs than 
asthmatic subjects and thus normal volunteer studies will 
always overestimate the side-effects of inhaled steroids. It is 
disappointing that the authors do not address this funda- 
mental problem. It could be argued that for the ratio of 
side-effects of FP to BUD the fact that it is done in normal 
subjects is irrelevant because although the detriment in 
cortisol will be less in the asthmatic subjects, the ratio 
would remain the same. However, this is not likely to be 
the case as different particle characteristics of the two 
inhalers may mean that they behave quite differently in the 
asthmatics to the normal subjects. In discussing previous 
studies the authors completely ignore a large number of 
studies which have the tremendous advantage of using 
inhaled steroids at the doses which would be appropriate 
for that patient’s asthma severity and measuring efficacy 
and safety within the same study. These studies, which were 
done in a far larger number of patients than the small- 
normal volunteer studies, give a quite different result. Ayres 
et al. compared FP 1 and 2 mg with budesonide 1.6 mg 
both in terms of efficacy and safety. The order of efficacy 
was budesonide 1.6 mg, FP 1 mg, FP 2 mg and the order of 
the cortisol was FP 1 mg, budesonide 1.6 mg, FP 2 mg. This 
is consistent with an efficacy ratio of approximately 2: 1 with 
no evidence for increased side-effects and runs counter to 
the authors’ argument that there is a 3:l ratio in terms of 
systemic side-effects. Ringdal et al. also showed greater 
efficacy of FP despite being used at half the dose of 
budesonide with slightly less effects on adrenocortical 
